{"analyses":[{"ciNumSides":"TWO_SIDED","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<0.01","pValueComment":"An exact Cochran-Armitage trend test was used to compare the distributions. In view of the large number of tests performed, we only refer to those with P-values \\<0.01 as statistically significant, with those for which 0.01 \\<P\\< 0.05 considered trends.","statisticalMethod":"Cochran-Armitage trend test"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"47"},{"groupId":"OG001","value":"84"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"47"},{"groupId":"OG001","value":"84"}],"units":"Participants"}],"description":"Here is the number of participants with adverse events. For a detailed list of adverse events, see the adverse event module.","groups":[{"description":"Participants received at least one protocol prescribed dose or higher of Romidepsin intravenously at 14mg/m\\^2 and at 17.5 mg/m\\^2 on days 1, 8, and 15 of a 28 day cycle.","id":"OG000","title":"Peripheral T-cell Lymphoma (PTCL)"},{"description":"Participants received at least one protocol prescribed dose or higher of Romidepsin intravenously at 14mg/m\\^2 and at 17.5 mg/m\\^2 on days 1, 8, and 15 of a 28 day cycle.","id":"OG001","title":"Cutaneous T-cell Lymphoma (CTCL)"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"147 months and 5 days","title":"Number of Participants With Adverse Events","type":"SECONDARY","unitOfMeasure":"participants"}